文献速递免疫规划传染病防控与疫情报告

COVID-19疫苗在日本参与者中的1/2期临床试验:中期结果报告

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
PubMed 文献 · Vaccine · 2022-05-13

这项随机、安慰剂对照的1/2期试验在60名健康日本成人中评估S-268019-b重组蛋白疫苗(2剂、间隔21天肌肉注射)的安全性及免疫原性,比较5 μg和10 μg抗原组与安慰剂。中期分析显示疫苗安全性良好,可诱导稳健的IgG和中和抗体,中和抗体滴度与COVID-19康复者血清相当,但需大规模临床试验进一步评估。

要点

  • 疫苗组大多数参与者反应原性为轻度,未观察到严重不良事件。
  • 5 μg和10 μg组在第36天和第50天均诱导稳健的IgG和中和抗体产生。
  • 中和抗体滴度与COVID-19康复者血清相当,但需大规模临床试验进一步评估。

核心结论

  • 基于中期分析,S-268019-b疫苗安全性良好,产生的中和抗体滴度与COVID-19康复者血清相当,但需大规模临床试验进一步评估。

研究设计与样本

  • 随机、安慰剂对照的1/2期试验,纳入60名健康日本成人,随机分配至S-910823抗原5 μg组(n=24)、10 μg组(n=24)或安慰剂组(n=12)。
  • S-268019-b重组蛋白疫苗计划为2次肌肉注射,间隔21天。

主要发现

  • 大多数参与者反应原性为轻度,未观察到严重不良事件。
  • 5 μg和10 μg组在第36天和第50天均诱导稳健的IgG和中和抗体产生。
  • 观察到以辅助性T细胞1型为主的免疫反应,表现为尖峰蛋白肽刺激下抗原特异性多功能CD4+ T细胞产生IFN-γ、IL-2和IL-4。

局限性

  • 原文为中期分析结果。
  • 原文指出需在大规模临床试验中进一步评估该疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. No serious adverse events were noted. For both regimens, vaccination resulted in robust IgG and neutralizing antibody production at days 36 and 50 and predominant T-helper 1-mediated immune reaction, as evident through antigen-specific polyfunctional CD4+ T-cell responses with IFN-γ, IL-2, and IL-4 production on spike protein peptides stimulation. Based on the interim analysis, the S-268019-b vaccine is safe, produces neutralizing antibodies titer comparable with that in convalescent serum from COVID-19-recovered patients. However, further evaluation of the vaccine in a large clinical trial is warranted.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Iwata S, Sonoyama T, Kamitani A, et al. Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 2022. PMID: 35606235. doi:10.1016/j.vaccine.2022.04.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。